// App-Quantinova.ai

PB1152 : Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B With Inhibitors

Researchers

Presenter

  • S. Rangarajan

Principal Investigators

  • A. Srivastava

  • O. Zulfikar

  • S. Kichou

  • Z. Qiu

  • S. Andersson

  • B. Mei

  • G. Young

Medical Centers

  • University of Southampton, Southampten, United Kingdom

  • Christian Medical College, Vellore, India, Vellore, Tamil Nadu, India

  • Istanbul University Onkology Institute, Istanbul, Turkey

  • BayCare Medical Group, Pediatric Hematology Oncology at St. Jospeh’s Children’s Hospital, Tampa, Florida, USA, Tampa, Florida, United States

  • Sanofi Genzyme, Paris, France, Paris, Ile-de-France, France

  • Sanofi, Bridgewater, NJ, USA, Bridgewater, New Jersey, United States

  • Sanofi, Cambridge, MA, USA, Cambridge, Massachusetts, United States

  • Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA, Los Angeles, California, United States

Locations

  • United Kingdom

  • India

  • Turkey

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT03417102

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved